abrdn Life Sciences Investors
HQL
78 hedge funds and large institutions have $74.4M invested in abrdn Life Sciences Investors in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 34 increasing their positions, 19 reducing their positions, and 7 closing their positions.
79% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 19
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
4% more capital invested
Capital invested by funds: $71.9M → $74.4M (+$2.54M)
0.21% more ownership
Funds ownership: 20.76% → 20.97% (+0.21%)
0% more funds holding
Funds holding: 78 → 78 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RL
RPO LLC
Stamford,
Connecticut
|
+$2.57M |
| 2 |
SCM
Saba Capital Management
New York
|
+$1.89M |
| 3 |
TJHA
Thomas J. Herzfeld Advisors
Miami Beach,
Florida
|
+$1.43M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$1.26M |
| 5 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$688K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$2.01M |
| 2 |
FHA
Flagship Harbor Advisors
Boston,
Massachusetts
|
-$1.87M |
| 3 |
LSC
Logan Stone Capital
Chicago,
Illinois
|
-$1.01M |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$978K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$271K |
HQL Hedge Fund Activity: Q2 2023 in Review
78 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q2 2023, worth a combined $74.4M — up 3.5% from $71.9M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new HQL positions and 7 closed out — a net gain of 1 holder — while 34 added to existing stakes and 19 trimmed.
The largest buyer was RPO LLC, opening a new position worth an estimated $2.57M. The largest seller was Raymond James & Associates, cutting an estimated $2.01M.
- 78 institutional investors held abrdn Life Sciences Investors (HQL) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $74.4M of abrdn Life Sciences Investors stock for Q2 2023, up 3.5% quarter-over-quarter.
- 8 funds opened new abrdn Life Sciences Investors positions in Q2 2023 and 7 closed out, a net change of +1 holder.
- The largest abrdn Life Sciences Investors buyer in Q2 2023 was RPO LLC, an estimated $2.57M added.
- The largest abrdn Life Sciences Investors seller in Q2 2023 was Raymond James & Associates, an estimated $2.01M sold.
Based on aggregated 13F filings for Q2 2023.